Want to see CTVA full AI Analyst Report?
Top Page
Corteva
(NYSE:CTVA)
Select Model
Select Model
Rating:64Neutral
Price Target:
$84.00
▼(-5.88% Downside)
Action:Reiterated
Date:08/07/26
CTVA’s score is primarily supported by solid underlying financial stability (notably low leverage) and a positive earnings update with raised 2026 guidance and margin/productivity momentum. Offsetting this, technical trends remain bearish and valuation looks expensive (high P/E with low yield), while the latest TTM revenue and free-cash-flow deterioration is a near-term risk to monitor.
Positive Factors
Conservative balance sheet
Corteva's low leverage and large equity base provide durable financial flexibility to fund R&D, seasonal working capital and the planned separation. This capitalization reduces refinancing risk during agricultural cycles and supports investment in product pipelines and shareholder returns over the medium term.
Negative Factors
TTM revenue and FCF deterioration
A large step-down in trailing revenue and free cash flow signals elevated volatility in cash generation and raises uncertainty around reinvestment capacity. Persistent declines can strain funding for R&D, separation costs and working capital, making execution on strategic plans more dependent on cyclical recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Corteva's low leverage and large equity base provide durable financial flexibility to fund R&D, seasonal working capital and the planned separation. This capitalization reduces refinancing risk during agricultural cycles and supports investment in product pipelines and shareholder returns over the medium term.
Read all positive factors
Corteva Key Performance Indicators (KPIs)
Any
Seed Sales by Segment
Tracks revenue from seed sales across various segments, indicating market demand and competitive positioning in the agriculture sector.
Tracks revenue from seed sales across various segments, indicating market demand and competitive positioning in the agriculture sector.
Data provided by:
The Fly
The FlyCorteva (CTVA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$50.57B
Dividend Yield0.94%
Average Volume (3M)3.89M
Price to Earnings (P/E)50.8
Beta (1Y)0.44
Revenue Growth3.70%
EPS Growth-26.39%
CountryUS
Employees21,500
SectorBasic Materials
Sector Strength58
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)1.51
Shares Outstanding667,196,000
10 Day Avg. Volume3,143,736
30 Day Avg. Volume3,887,893
Financial Highlights & Ratios
PEG Ratio1.89
Price to Book (P/B)1.89
Price to Sales (P/S)2.62
P/FCF Ratio16.19
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$94.00Price Target Upside5.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)3.76
Revenue Forecast (FY)$18.15B
Corteva Business Overview & Revenue Model
Company Description
Corteva, Inc. operates in the agriculture business. The company operates through two segments, Seed and Crop Protection. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms. It offers trait tec...
How the Company Makes Money
Corteva makes money primarily by selling agricultural inputs through two major revenue streams. (1) Seed: Corteva sells proprietary seeds (notably corn and soybean, along with other crops) and earns revenue from seed product sales that incorporate...
Corteva Earnings Call Summary
Earnings Call Date:Jul 30, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 11, 2026
Earnings Call Sentiment Positive
The call delivered a broadly positive message: strong first-half execution drove revenue, margin and EBITDA gains; management raised full-year guidance and reported meaningful progress on the planned separation with dis-synergies largely mitigated. Notable challenges include crop protection pricing pressure (especially in Brazil), near-term cash flow impacts from one-time items, seasonal Q3 weakness and farmer margin/credit constraints in Latin America. Overall the company emphasized durable technology-led demand, productivity gains, and a healthy new product and licensing pipeline, while acknowledging localized and timing risks.Positive Updates
Raised Full-Year Guidance
Operating EBITDA guidance increased to $4.1B–$4.3B and operating EPS to $3.60–$3.80. At the midpoint this implies ~9% EBITDA growth and ~11% EPS growth versus prior year.
Negative Updates
Crop Protection Pricing Pressure
Crop protection pricing under pressure, particularly in Latin America/Brazil. Company expects pricing decline in the second half of low-to-mid single digits (and noted pockets of more competitive pricing in Brazil).
Read all updates
Q2-2026 Updates
Positive
Negative
Raised Full-Year Guidance
Operating EBITDA guidance increased to $4.1B–$4.3B and operating EPS to $3.60–$3.80. At the midpoint this implies ~9% EBITDA growth and ~11% EPS growth versus prior year.
Read all positive updates
Company Guidance
Corteva raised full‑year 2026 guidance, now expecting operating EBITDA of $4.1–$4.3 billion and operating EPS of $3.60–$3.80 (midpoints imply ~9% EBITDA growth and ~11% EPS growth versus last year) with an operating EBITDA margin target of 22.5%–23.5%; that outlook is supported by a strong first half (net sales $11.3B, +4% YoY, organic +2%; Q2 net sales $6.4B), first‑half operating EBITDA $3.7B (+10%), operating EPS +14%, and margin expansion of nearly 200 basis points to ~32.8%. Management assumes seed organic growth of low‑single digits, crop protection volumes up high‑single digits (driven by new products) with pricing down low‑ to mid‑single digits, Brazil corn area ~flat, and typical seasonality (a Q3 operating EBITDA loss similar to 2024 with most second‑half earnings in Q4); year‑to‑date drivers include >$160M of cost/productivity savings, ~$90M improvement in net royalties, and an ~$85M favorable currency impact, and absent one‑time items they expect free cash flow conversion in line with prior midterm targets.Corteva Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
82
Very Positive
Cash Flow
56
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.81B | 17.40B | 16.91B | 17.23B | 17.45B | 15.65B |
| Gross Profit | 8.63B | 8.23B | 7.38B | 7.31B | 7.02B | 6.43B |
| EBITDA | 3.24B | 3.07B | 2.73B | 2.54B | 2.73B | 3.62B |
| Net Income | 1.01B | 1.09B | 907.00M | 735.00M | 1.15B | 1.76B |
Balance Sheet | ||||||
| Total Assets | 41.64B | 42.84B | 40.83B | 43.00B | 42.62B | 42.34B |
| Cash, Cash Equivalents and Short-Term Investments | 2.37B | 4.53B | 3.17B | 2.74B | 3.31B | 4.54B |
| Total Debt | 4.88B | 2.58B | 2.70B | 2.49B | 1.31B | 1.12B |
| Total Liabilities | 16.24B | 18.46B | 16.80B | 17.72B | 17.08B | 16.72B |
| Stockholders Equity | 25.16B | 24.14B | 23.79B | 25.04B | 25.30B | 25.38B |
Cash Flow | ||||||
| Free Cash Flow | 629.00M | 2.81B | 1.55B | 1.17B | 267.00M | 2.15B |
| Operating Cash Flow | 1.21B | 3.41B | 2.15B | 1.77B | 872.00M | 2.73B |
| Investing Cash Flow | -592.00M | -543.00M | -589.00M | -1.99B | -632.00M | -362.00M |
| Financing Cash Flow | -301.00M | -1.64B | -1.20B | -99.00M | -1.18B | -1.27B |
Corteva Technical Analysis
Negative
89.25
Price Trends
81.58
Negative
81.33
Negative
75.72
Positive
Market Momentum
-2.29
Positive
37.53
Neutral
22.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTVA, the sentiment is Negative. The current price of 89.25 is above the 20-day moving average (MA) of 82.14, above the 50-day MA of 81.58, and above the 200-day MA of 75.72, indicating a neutral trend. The MACD of -2.29 indicates Positive momentum. The RSI at 37.53 is Neutral, neither overbought nor oversold. The STOCH value of 22.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTVA.
Corteva Risk Analysis
Corteva disclosed 31 risk factors in its most recent earnings report. Corteva reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Corteva Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $17.71B | 8.75 | 40.41% | 1.60% | 20.04% | 76.29% | |
64 Neutral | $50.57B | 50.78 | 4.08% | 0.81% | 3.70% | -26.39% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
57 Neutral | $6.96B | 22.94 | 5.02% | 3.61% | 10.92% | -16.91% | |
53 Neutral | $3.59B | 48.75 | -21.87% | 3.81% | -1.95% | 44.91% | |
51 Neutral | $6.92B | 108.05 | 0.36% | 3.95% | 8.84% | -167.87% | |
45 Neutral | $1.27B | -0.46 | -118.57% | 7.26% | -21.31% | -2884.91% |
* Basic Materials Sector Average
CTVA
Corteva
76.68
5.61
7.89%
CF
Cf Industries Holdings
118.30
34.14
40.57%
FMC
FMC
10.15
-26.02
-71.94%
MOS
Mosaic Co
21.61
-9.76
-31.11%
SMG
Scotts Miracle-Gro Company
60.94
1.45
2.44%
ICL
Icl
5.55
-0.43
-7.21%
Corteva Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Corteva’s Vylor launches note exchange ahead separation
Positive
Aug 6, 2026
On August 6, 2026, Corteva announced that Vylor, its seed business subsidiary, has launched private exchange offers and related consent solicitations for all outstanding senior notes due 2030, 2032 and 2033 issued by EIDP, Inc., another Corteva su...
Business Operations and StrategyExecutive/Board Changes
Corteva Details Board for Future Crop Protection Spinoff
Positive
Jun 29, 2026
On June 29, 2026, Indianapolis-based Corteva Inc. outlined the intended board of directors for its future standalone crop protection business, ahead of a planned separation in the fourth quarter of 2026. Greg Page, former Cargill chairman and CEO,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.